Evidence map›Paper›PMID 33713207›Full record

ArticleInternational journal of clinical oncology2021

The prevalence of secondary neoplasms in acromegalic patients: possible preventive and/or protective role of metformin.

Denise Costa, Filippo Ceccato, Rosa Lauretta, Valeria Mercuri, Tania D'Amico, Corrado De Vito, Carla Scaroni, Marialuisa Appetecchia, Patrizia Gargiulo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Uterine fibroids in women diagnosed with acromegaly: a systematic review.Reviews in endocrine & metabolic disorders · 2024
    Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Denise CostaDepartment of Experimental Medicine, Endocrinology-Pituitary Disease, "Sapienza" University of Rome, Rome, Italy.
Filippo CeccatoEndocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, Padua, Italy.
Rosa LaurettaOncological Endocrinology Unit, IRCCS, "Regina Elena" National Cancer Institute, Rome, Italy.
Valeria MercuriDepartment of Experimental Medicine, Endocrinology-Pituitary Disease, "Sapienza" University of Rome, Rome, Italy.
Tania D'AmicoDepartment of Experimental Medicine, Endocrinology-Pituitary Disease, "Sapienza" University of Rome, Rome, Italy.
Corrado De VitoDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy.
Carla ScaroniEndocrinology Unit, Department of Medicine DIMED, University-Hospital of Padua, Padua, Italy.
Marialuisa AppetecchiaOncological Endocrinology Unit, IRCCS, "Regina Elena" National Cancer Institute, Rome, Italy.
Patrizia GargiuloDepartment of Experimental Medicine, Endocrinology-Pituitary Disease, "Sapienza" University of Rome, Rome, Italy. patrizia.gargiulo@uniroma1.it.ORCID http://orcid.org/0000-0003-1216-2034
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcromegaly is a rare disease due to chronic growth hormone (GH) excess and the consequent increase in insulin-like growth factor-1 (IGF-1) levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. The association between hyperinsulinemia/impaired glucose tolerance and an increased risk of cancer has been clarified. Insulin has a mitogenic effect through its interaction with the IGF-1 receptor (IGF-1R) that also binds IGF-1. On the other hand, metformin, an anti-hyperglycemic drug that decreases serum levels of insulin and IGF-1, could have a protective role in the treatment of endocrine tumors.

methodsA retrospective, observational, multicenter study in 197 acromegalic patients, receiving/not receiving metformin, was performed to assess whether the prevalence of neoplasms might be correlated with insulin resistance and could eventually be modified by metformin treatment.

resultsIn general, the occurrence of secondary neoplasia among our patients was significantly (pV = 0.035) associated with a positive family history of malignancy and with disease duration; a trend towards significance was observed in patients aged > 50 years. Acromegalic subjects who had undergone surgery showed a lower probability of developing a malignant tumor, whereas a higher prevalence of malignancies was observed in obese patients. No significant statistical difference was found when comparing metformin-treated or -untreated subjects for the presence of a second tumor. More interestingly, a trend towards statistical significance (pV = 0.065) was demonstrated in the metformin-treated group for the onset of a benign neoplasm.

conclusionMetformin could act directly on tumor cell metabolism and may have an adjuvant role in benign lesion progression.

Indexed as

AcromegalyBenign neoplasmMetforminSecondary tumor prevalence

Identifiers

PMID33713207
PMCPMC8134278
OpenAlexW3135234177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.